BIOAQ BioAmber

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against BioAmber Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Lundin Law PC, a shareholder rights firm announces a class action lawsuit against BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA). Investors who purchased or otherwise acquired BioAmber shares between January 23, 2017 and March 16, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 17, 2017 lead plaintiff deadline.

To participate in this class action lawsuit, click here, or call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

BioAmber announced that trading announced poor financial outcomes for the 2016 fiscal year, failing to meet its previously issued revenue guidance by $1.3 million. On an earnings conference call, President Fabrice Orecchioni of BioAmber, alleged the poor results were due to “pricing pressures” and “a disruption from a large customer that was expected to purchase 2.8 million of succinic acid in Q4 2016, but due to a technical problem in its manufacturing facility postponed the order to 2017.”

When this news was revealed to the investing public, the value of BioAmber dropped, causing investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

EN
21/03/2017

Underlying

BIOAQBioAmber

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioAmber

Free Trial
BIOAQ BIOAMBER

Six Directors bought 219,998 shares at 0.750USD.

Six Directors at Bioamber Inc bought 219,998 shares at 0.750USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

08/17/17 August 17, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

DEADLINE ALERT: Brower Piven Alerts Shareholders of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

May 9, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

BIOA Investors: GPM Reminds Investors of the May 17 Deadline in the Cl...

LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the May 17, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 t...

May 9, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

The Law Offices of Howard G. Smith Announces the Filing of a Securitie...

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased BioAmber Inc. (“BioAmber” or the “Company”) (NYSE: BIOA) securities (1) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 (the “Offering”); and/or (2) between January 23, 2017 and March 16, 2017, inclusive (the “Class Period”). BioAmber investors have until May 17, 2017 to file a lead plaintiff motion. Investors suffering l...

April 13, 2017 1 EN
 PRESS RELEASE
Free
BIOAQ BIOAMBER

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses I...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of New York on behalf of purchasers of BioAmber Inc. (NYSE: BIOA) (BioAmber or the “Company”) pursuant and/or traceable to BioAmber’s secondary public offering on or about January 23, 2017 and/or on the open market from January 23, 2017 through March 16, 2017, inclusive (the “Class Period”). Investors who w...

April 3, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch